Login to Your Account

Galena Biopharma implodes as PRESENT review puts cancer vaccine Neuvax future in doubt

By Jennifer Boggs
Managing Editor

Wednesday, June 29, 2016

With the bulk of Galena Biopharma Inc.'s value riding on cancer vaccine Neuvax, the firm's shares predictably plunged to a new 52-week low Wednesday as an IDMC recommended the PRESENT phase III study in breast cancer be stopped.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription